‘Hey Monster' is the Pokemon game we needed for our smartphones'
SolarCity will try to attract institutional shareholders to approve the merger by showing off its latest product
The battery swap will help Tesla in meeting the charging demand once Model 3 and Tesla Semi are out
Wedbush reiterates an Outperform rating on Amazon heading into 3Q results
Tesla is expected to report financials on a GAAP basis, prompting Oppenheimer to update its model
We keep tabs on Amazon’s financial performance in the third quarter
Tesla was ranked at No.25 out of the 29 brands due to the problems of Model X SUV by Consumer Reports
Does Apple have the ability to revert focus on "user experience" than hardware?
Oppenheimer restates its 'Perform' rating on Apple, saying ASP boost wouldn’t ease concerns with iPhone 7 cycle
A phased beta rollout has begun for the video calling feature on WhatsApp
Smartwatch shipments have experienced a downfall of more than 50 percent during its third quarter
Now you can enjoy Android 7.0 Nougat on your Nexus 5
Analyst Justin Post discussed the company’s weakening position in his recent thesis, while he continued that there are few developments that might not go in its favor
RBC Capital Markets analyst believes that Chesapeake's lower cost structure and improved margin outlook over the next few years highlighted in the recently held analyst day deserves an applaud
With the thicket of fossil fuel regulations in California, would the energy giant benefit from the Richmond refinery renovation?
Although several financial and operational challenges stand in the company’s way to success, the appreciable progress made over the past few years and in particular, the financial overhaul in 2016 under a challenging commodity price environment signals good times ahead for the company
The state owned company has agreed to settle lawsuits from Pacific Investment Management Co. along with three other investors that were reportedly harmed by the corruption scandal
We take a look at the reasons behind Moody’s decision to upgrade Petrobras’ credit rating
The Food and Drug Administration cleared Keytruda for use in previously untreated lung cancer patients
Leerink Partners analyst raised price target on Gilead stock based on NASH data feedback from an expert
GlaxoSmithKline is due to report third quarter earnings on Wednesday
The company seems to be better at raising prices of its drugs, rather than boosting its stock price
Mylan's shares continue taking a beat as the EpiPen controversy is not abating